Financière de Tubize stock
TUB.BRBRUFinancière de Tubize S.A., HealthcareISIN BE0003823409
50Score 50 out of 100, Neutral
Price and trend
66 / 100
Price history
+20% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 17% above it.
Since August 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 2.2% below its 52-week high. Largest decline in 20 years: 78% (May 2007 to October 2008).
Chart figures for advanced users
- SMA 50$214.94
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$231.02
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$188.38
- The lowest closing price of the last twelve months.
- Resistance$275.39
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Financière de Tubize S.A. belongs to the Biotechnology industry (Belgium) and, with a market value of $11.99B, is number 30 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 50 out of 100 (Neutral): rank 385 of 714 in Healthcare, median 53.
- The P/E is 109.5 (Biotechnology median 21.3, own median of recent years 25.4).
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Reliable dividendNo dividend cut for over 26 years.
- More cash than debtCash $1.41M, financial debt $0.Stability 88
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 62
Weaknesses
- Richly valuedP/E 109.5, Biotechnology median 21.3, own median 25.4.Valuation 10
- Earnings per share fallingDown 18.6% a year since 2020.Growth 32
Its standout strengths are stability and momentum, while profitability and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- price near its 52-week high
Valuation
Valuation signal
OvervaluedClosing price of 11 Nov 2026, used by the daily score.
A fair value is not meaningful here, so the signal follows the valuation grade.
Valuation metrics
The model puts the fair value at less than a quarter of the share price. That says more about the assumptions than about the company, so a fair value is not meaningful here and the valuation relies on the P/E and the other metrics.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. From 2024 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterNo financial debt is reported on the balance sheet.
Earnings
- Next earnings
- No date announced.
- Last reported
- 3 Aug 2026EPS reported $2.51
What happened at Financière de Tubize
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 50
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Kymera TherapeuticsKYMR $13.5B45
- Summit TherapeuticsSMMT $13.27B39
- Madrigal PharmaceuticalsMDGL $12.67B34
- Pharmaron Beijing300759.SZ $12.15B58
- Halozyme TherapeuticsHALO $11.59B80
- Bio-TechneTECH $11.44B65
- BioMarin PharmaceuticalBMRN $11.3B50
- VaxcytePCVX $10.8B46
ETFs that hold Financière de Tubize
Held by 90 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares EURO STOXX Small UCITS ETFIQQS | 1.60% | 0.40% | €405.6M |
| iShares STOXX Europe Small 200 UCITS ETF (DE)EXSE | 0.72% | 0.20% | €632.25M |
| iShares MSCI Europe Mid-Cap Equal Weight UCITS ETFCEMT | 0.51% | 0.25% | €36.18M |
Show 5 more
| iShares MSCI EMU Mid Cap UCITS ETF EURIS3H | 0.40% | 0.49% | €567.29M |
| State Street SPDR MSCI Europe Health Care UCITS ETFSPYH | 0.27% | 0.18% | €653.55M |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 0.27% | 0.46% | €729.65M |
| iShares MSCI Europe Health Care Sector UCITS ETFESIH | 0.27% | 0.18% | €954.9M |
| Xtrackers MSCI Europe Health Care Screened UCITS ETF 1CDXSE | 0.27% | 0.17% | €363.6M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = €0.8987)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 10 Nov 2026, previously Weak
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.